Full-Time

IT Support Engineer

Posted on 12/12/2024

Syndax

Syndax

201-500 employees

Develops therapies for difficult-to-treat cancers

Compensation Overview

$100k - $110k/yr

+ Equity Offering + Annual Target Bonuses

Mid, Senior

New York, NY, USA

Requires working from Syndax’s primary New York City office.

Category
Customer Experience & Support
IT Support
IT & Security
Required Skills
PowerShell
Microsoft Azure
iOS/Swift
Android Development
Requirements
  • A bachelor’s degree in computer science, Information Technology, or similar.
  • 3-5 years of experience as a Helpdesk Support Specialist. Biotech industry experience a plus!
  • Exceptional interpersonal and communication skills, both written and verbal.
  • Proven ability to problem-solve and perform root-cause analysis.
  • Knowledge of O365, Azure AD, Intune, and Azure Cloud Computing Resources. Knowledge of PowerShell preferred.
  • Experience with Windows OS, desktop applications including Microsoft Office with add-ins, web browsers, development tools and libraries.
  • Familiarity with writing documentation to capture process and technology details for repeatable and verifiable high-quality results.
  • Experience assembling and moving physical computer systems and hardware, replacing/updating peripherals, and connections.
  • Exposure to mobile device management including iOS and Android.
Responsibilities
  • First point of contact for daily operational technology support, including support of laptop computers, tablets, mobile devices, virtual desktops, and SaaS applications for a hybrid work force.
  • Participate in rotating on-call schedule for after-hours support.
  • Troubleshoot technology issues spanning the operating system through desktop & cloud applications.
  • Facilitate onboarding & offboarding, including the deployment of assets via Autopilot and the return of workstations.
  • Effectively triage requests via ticketing system (FreshService) while complying with established SLAs and ensuring customer satisfaction.
  • Develop documentation for various technology tasks and troubleshooting steps.
  • Execute, create, and evolve standardized technology solutions and operating procedures.
  • Collaborate with team members on projects and tasks, as assigned.
  • Maintain security across systems in accordance with defined processes and procedures.

Syndax Pharmaceuticals develops and commercializes therapies specifically for cancer patients, focusing on challenging cases like hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The company conducts research and clinical trials to test the safety and effectiveness of its drugs, aiming to bring new treatments to market after receiving regulatory approval. Syndax's main product, Entinostat, is currently in clinical trials combined with Exemestane for treating HR+, HER2- breast cancer. Unlike many competitors, Syndax targets underserved patient populations and seeks to establish partnerships to enhance its market presence. The goal of Syndax is to improve cancer treatment options through the development of innovative therapies and to support its operations through strategic capital raises.

Company Size

201-500

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2005

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval of Niktimvo™ offers first-mover advantage in chronic GVHD treatment.
  • Positive Augment-101 trial data enhances Revuforj®'s marketability and adoption.
  • Strategic partnerships, like with Incyte, expand resources and market reach.

What critics are saying

  • Potential fiduciary duty breach investigation could affect investor confidence.
  • Reliance on clinical trial success, like Entinostat, poses growth risks.
  • Inducement grants may lead to shareholder dilution, affecting stock value.

What makes Syndax unique

  • Syndax focuses on innovative cancer therapies, targeting difficult-to-treat cancers.
  • The company develops unique treatments like Niktimvo™, targeting CSF-1R for chronic GVHD.
  • Syndax's pipeline includes Revuforj®, a menin inhibitor for acute leukemia treatment.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

7%

1 year growth

10%

2 year growth

5%
PR Newswire
Jan 30th, 2025
Syndax Announces Participation In February Investor Conferences

WALTHAM, Mass., Jan. 30, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:Guggenheim SMID Cap Biotech Conference in New York, NY with a fireside chat on Thursday, February 6, 2025 , at 10:30 a.m. ETin with a fireside chat on , at Citi's 2025 Virtual Oncology Leadership Summit with a fireside chat on Wednesday, February 19, 2025 , at 9:00 a.m. ETA live webcast of the fireside chats will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.About SyndaxSyndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor

PR Newswire
Jan 15th, 2025
Incyte And Syndax Announce U.S. Food And Drug Administration (Fda) Approval Of Niktimvo™ (Axatilimab-Csfr) 9 Mg And 22 Mg Vial Sizes

– U.S. launch expected in early February –– Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drivers of inflammation and fibrosis –– Pivotal data from the AGAVE-201 trial supporting FDA approval show treatment with Niktimvo resulted in durable responses across all organs studied and patient subgroups –WILMINGTON, Del. and WALTHAM, Mass., Jan. 15, 2025 /PRNewswire/ -- Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Niktimvo™ (axatilimab-csfr) in 9 mg and 22 mg vial sizes. The Companies expect product to be available for order in the U.S

Stock Titan
Jan 7th, 2025
Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference

Syndax announces presentation at 43rd Annual J.P. Morgan Healthcare Conference.

PR Newswire
Jan 3rd, 2025
Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

WALTHAM, Mass., Jan. 3, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on January 1, 2025 the Company granted inducement awards to purchase up to 123,100 shares of common stock to five new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.About SyndaxSyndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.Syndax ContactSharon KlahreSyndax Pharmaceuticals, Inc.[email protected]Tel 781.684.9827SOURCE Syndax Pharmaceuticals, Inc

ETF Daily News
Dec 29th, 2024
Stifel Financial Corp Invests $327,000 in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Stifel Financial Corp invests $327,000 in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX).

INACTIVE